Q3 Earnings Forecast for ABEO Issued By Zacks Small Cap

Abeona Therapeutics Inc (NASDAQ:ABEO) – Analysts at Zacks Small Cap issued their Q3 2025 earnings per share estimates for Abeona Therapeutics in a report released on Monday, March 24th. Zacks Small Cap analyst D. Bautz anticipates that the biopharmaceutical company will post earnings of ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at $0.40 EPS.

Other analysts have also issued research reports about the stock. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 24th. Oppenheimer started coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They set an “outperform” rating and a $16.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research note on Monday, March 24th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Abeona Therapeutics Price Performance

Shares of ABEO stock opened at $4.97 on Thursday. The firm’s 50-day moving average is $5.42 and its two-hundred day moving average is $5.81. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $8.45. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The company has a market capitalization of $216.05 million, a PE ratio of -1.85 and a beta of 1.79.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.19.

Institutional Trading of Abeona Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Twinbeech Capital LP purchased a new position in shares of Abeona Therapeutics during the fourth quarter worth $58,000. Squarepoint Ops LLC acquired a new position in Abeona Therapeutics in the 4th quarter valued at about $67,000. Jane Street Group LLC purchased a new stake in Abeona Therapeutics during the third quarter worth about $84,000. Oxford Asset Management LLP purchased a new stake in Abeona Therapeutics during the fourth quarter worth about $118,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics during the third quarter worth about $151,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.